Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more
Zealand Pharma A/S (ZLDPF) - Total Assets
Latest total assets as of September 2025: $2.63 Billion USD
Based on the latest financial reports, Zealand Pharma A/S (ZLDPF) holds total assets worth $2.63 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zealand Pharma A/S - Total Assets Trend (2007–2024)
This chart illustrates how Zealand Pharma A/S’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zealand Pharma A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Zealand Pharma A/S's total assets of $2.63 Billion consist of 89.7% current assets and 10.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.1% |
| Accounts Receivable | $138.97 Million | 1.5% |
| Inventory | $10.70 Million | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.62 Million | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Zealand Pharma A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zealand Pharma A/S's current assets represent 89.7% of total assets in 2024, a decrease from 95.5% in 2007.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2024, down from 93.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Zealand Pharma A/S Competitors by Total Assets
Key competitors of Zealand Pharma A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Zealand Pharma A/S - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zealand Pharma A/S generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Zealand Pharma A/S is currently not profitable relative to its asset base.
Zealand Pharma A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 35.49 | 2.16 |
| Quick Ratio | 2.21 | 35.49 | 2.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.43 Billion | $ 8.47 Billion | $ 667.30 Million |
Zealand Pharma A/S - Advanced Valuation Insights
This section examines the relationship between Zealand Pharma A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 380.1% |
| Total Assets | $9.51 Billion |
| Market Capitalization | $3.46 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zealand Pharma A/S's assets below their book value (0.36 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Zealand Pharma A/S's assets grew by 380.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zealand Pharma A/S (2007–2024)
The table below shows the annual total assets of Zealand Pharma A/S from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.51 Billion | +380.08% |
| 2023-12-31 | $1.98 Billion | +28.59% |
| 2022-12-31 | $1.54 Billion | -25.53% |
| 2021-12-31 | $2.07 Billion | +7.43% |
| 2020-12-31 | $1.92 Billion | +20.32% |
| 2019-12-31 | $1.60 Billion | +30.06% |
| 2018-12-31 | $1.23 Billion | +66.81% |
| 2017-12-31 | $737.24 Million | +6.13% |
| 2016-12-31 | $694.63 Million | +9.44% |
| 2015-12-31 | $634.69 Million | +6.36% |
| 2014-12-31 | $596.76 Million | +72.02% |
| 2013-12-31 | $346.91 Million | -33.41% |
| 2012-12-31 | $520.98 Million | +10.97% |
| 2011-12-31 | $469.48 Million | +4.20% |
| 2010-12-31 | $450.55 Million | +183.94% |
| 2009-12-31 | $158.68 Million | -29.55% |
| 2008-12-31 | $225.24 Million | -14.48% |
| 2007-12-31 | $263.37 Million | -- |